PL2300455T3 - Sole 2-fluoro-N-metylo-4-[7-(chinolin-6-ylometylo)imidazo[1,2-b][1, 2,4)triazyn-2-ylo)benzamidu i procesy związane z ich wytworzeniem - Google Patents
Sole 2-fluoro-N-metylo-4-[7-(chinolin-6-ylometylo)imidazo[1,2-b][1, 2,4)triazyn-2-ylo)benzamidu i procesy związane z ich wytworzeniemInfo
- Publication number
- PL2300455T3 PL2300455T3 PL09751439T PL09751439T PL2300455T3 PL 2300455 T3 PL2300455 T3 PL 2300455T3 PL 09751439 T PL09751439 T PL 09751439T PL 09751439 T PL09751439 T PL 09751439T PL 2300455 T3 PL2300455 T3 PL 2300455T3
- Authority
- PL
- Poland
- Prior art keywords
- methyl
- triazin
- quinolin
- imidazo
- benzamide
- Prior art date
Links
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical class C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5499508P | 2008-05-21 | 2008-05-21 | |
| PCT/US2009/044622 WO2009143211A2 (en) | 2008-05-21 | 2009-05-20 | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| EP09751439.2A EP2300455B1 (en) | 2008-05-21 | 2009-05-20 | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2300455T3 true PL2300455T3 (pl) | 2018-02-28 |
Family
ID=41058602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09751439T PL2300455T3 (pl) | 2008-05-21 | 2009-05-20 | Sole 2-fluoro-N-metylo-4-[7-(chinolin-6-ylometylo)imidazo[1,2-b][1, 2,4)triazyn-2-ylo)benzamidu i procesy związane z ich wytworzeniem |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US8420645B2 (enExample) |
| EP (2) | EP3287449A3 (enExample) |
| JP (2) | JP6022158B2 (enExample) |
| KR (1) | KR101706784B1 (enExample) |
| CN (4) | CN108586463A (enExample) |
| AR (3) | AR071873A1 (enExample) |
| BR (1) | BRPI0912882A2 (enExample) |
| CA (1) | CA2724742C (enExample) |
| CL (1) | CL2009001250A1 (enExample) |
| CO (1) | CO6300934A2 (enExample) |
| CY (1) | CY1119813T1 (enExample) |
| DK (1) | DK2300455T3 (enExample) |
| EA (1) | EA021364B1 (enExample) |
| EC (1) | ECSP10010685A (enExample) |
| ES (1) | ES2643363T3 (enExample) |
| HK (1) | HK1251568A1 (enExample) |
| HR (1) | HRP20171528T1 (enExample) |
| HU (1) | HUE034716T2 (enExample) |
| IL (3) | IL209229A (enExample) |
| LT (1) | LT2300455T (enExample) |
| MA (1) | MA32405B1 (enExample) |
| MX (3) | MX393622B (enExample) |
| MY (3) | MY187131A (enExample) |
| NZ (2) | NZ589622A (enExample) |
| PL (1) | PL2300455T3 (enExample) |
| PT (1) | PT2300455T (enExample) |
| SI (1) | SI2300455T1 (enExample) |
| TW (1) | TWI472529B (enExample) |
| WO (1) | WO2009143211A2 (enExample) |
| ZA (1) | ZA201008212B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2560435T3 (es) | 2006-11-22 | 2016-02-19 | Incyte Holdings Corporation | Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa |
| MX393622B (es) * | 2008-05-21 | 2025-03-24 | Incyte Corp | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas. |
| JP5714030B2 (ja) * | 2010-02-03 | 2015-05-07 | インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン |
| UY34329A (es) | 2011-09-15 | 2013-04-30 | Novartis Ag | Compuestos de triazolopiridina |
| DE102013100596B4 (de) | 2012-01-27 | 2023-09-07 | Samsung Electronics Co. Ltd. | Nichtflüchtiges Speichersystem mit Programmier- und Löschverfahren und Blockverwaltungsverfahren |
| CN110507654A (zh) * | 2012-04-03 | 2019-11-29 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
| AU2013302702A1 (en) * | 2012-08-16 | 2015-02-19 | Novartis Ag | Combination of Pl3K inhibitor and c-Met inhibitor |
| DK2976106T3 (da) * | 2013-03-21 | 2021-06-14 | Array Biopharma Inc | Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer |
| WO2014174478A1 (en) | 2013-04-26 | 2014-10-30 | Novartis Ag | Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| DK3172209T3 (da) | 2014-07-25 | 2021-02-22 | Novartis Ag | Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid |
| WO2016011658A1 (en) * | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| KR20170036037A (ko) | 2014-07-31 | 2017-03-31 | 노파르티스 아게 | 조합 요법 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| EP4378957A3 (en) | 2015-07-29 | 2024-08-07 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| BR112018015386A2 (pt) | 2016-01-27 | 2019-03-19 | Universität Zürich | uso de moduladores de receptor gabaa para tratamento de prurido |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| CN106496000A (zh) * | 2016-10-19 | 2017-03-15 | 蚌埠学院 | 一种3‑氟‑4‑溴‑苯乙酮的合成方法 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| US11312783B2 (en) | 2017-06-22 | 2022-04-26 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| BR112020021104A2 (pt) * | 2018-04-18 | 2021-02-23 | Neurocycle Therapeutics, Inc | compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos |
| CN110526916B (zh) * | 2018-05-23 | 2021-07-13 | 海创药业股份有限公司 | 氘代Capmatinib化合物及其用途 |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021165818A1 (en) * | 2020-02-17 | 2021-08-26 | Novartis Ag | Process and intermediates for the preparation of 2-fluoro-n-methyl-4-[7-quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2yl]benzamide |
| EP4159238A4 (en) * | 2020-06-02 | 2024-08-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY |
| CN111825678A (zh) * | 2020-06-05 | 2020-10-27 | 连庆泉 | 一种卡马替尼的制备方法 |
| WO2022007752A1 (zh) * | 2020-07-06 | 2022-01-13 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法 |
| WO2022063869A2 (en) * | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| CN112480017A (zh) * | 2020-11-13 | 2021-03-12 | 金仓(上海)医药生物科技有限公司 | 一种3-氨基-1,2,4-三嗪的制备方法 |
| CN114621155A (zh) * | 2020-12-14 | 2022-06-14 | 四川科伦药物研究院有限公司 | 一种制备卡马替尼的方法 |
| CN114853762B (zh) * | 2021-02-03 | 2026-03-06 | 四川科伦药物研究院有限公司 | 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途 |
| EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| CN113896732B (zh) * | 2021-10-13 | 2023-09-12 | 沈阳红旗制药有限公司 | 抗癌药物卡马替尼的制备方法及其应用 |
| WO2023249994A1 (en) * | 2022-06-22 | 2023-12-28 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN119775203B (zh) * | 2024-11-29 | 2025-11-14 | 河北科技大学 | 一种卡马替尼中间体6-(3,3-二乙氧基丙基)喹啉的合成方法 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1411859A (en) | 1920-12-08 | 1922-04-04 | Marchand Robert | Process for preparing hydrate of terpin |
| US2837520A (en) | 1955-05-26 | 1958-06-03 | Ind Chimica Profarmaco S R L | Fluorescent materials on the basis of tetrazoindenes |
| US4220450A (en) | 1978-04-05 | 1980-09-02 | Syva Company | Chemically induced fluorescence immunoassay |
| US4209621A (en) | 1979-04-27 | 1980-06-24 | American Cyanamid Company | (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines |
| US4405619A (en) | 1981-09-02 | 1983-09-20 | Diamond Shamrock Corporation | Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines |
| DE3311753A1 (de) | 1983-03-31 | 1984-10-04 | Hoechst Ag, 6230 Frankfurt | Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung - |
| DE3421029C2 (de) | 1984-06-06 | 1986-04-24 | Walter Steinhausen Mathis | Verfahren und Vorrichtung zum trockenen Bedrucken eines Werkstückes unter Verwendung einer Heißprägefolie |
| JPS6337347A (ja) | 1986-08-01 | 1988-02-18 | Fuji Photo Film Co Ltd | 直接ポジカラ−画像形成方法 |
| JPS63199347A (ja) | 1987-02-14 | 1988-08-17 | Konica Corp | 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料 |
| JPS63310891A (ja) | 1987-06-12 | 1988-12-19 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリダジン化合物 |
| US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| JPH0313934A (ja) | 1989-06-12 | 1991-01-22 | Konica Corp | ハロゲン化銀写真感光材料 |
| IL96432A0 (en) | 1989-11-30 | 1991-08-16 | Schering Ag | Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives |
| JP2664264B2 (ja) | 1990-02-15 | 1997-10-15 | 富士写真フイルム株式会社 | ハロゲン化銀写真乳剤及びこれを用いた写真感光材料 |
| FR2662163A1 (fr) | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
| JPH04251243A (ja) | 1991-01-09 | 1992-09-07 | Konica Corp | ハロゲン化銀写真感光材料 |
| FR2671551B1 (fr) | 1991-01-15 | 1993-03-12 | Adir | Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| JPH05232618A (ja) | 1992-02-21 | 1993-09-10 | Konica Corp | ハロゲン化銀写真感光材料 |
| DE4309285A1 (de) | 1993-03-23 | 1994-09-29 | Boehringer Ingelheim Kg | Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung |
| ES2137113B1 (es) | 1997-07-29 | 2000-09-16 | Almirall Prodesfarma Sa | Nuevos derivados de triazolo-piridazinas heterociclicos. |
| JP4251243B2 (ja) | 1998-11-26 | 2009-04-08 | 株式会社日立メディコ | 領域拡張装置 |
| JP4025468B2 (ja) | 1999-07-29 | 2007-12-19 | 三井化学株式会社 | 有機電界発光素子 |
| RU2264403C2 (ru) | 1999-11-10 | 2005-11-20 | Орто-Макнейл Фармасьютикал, Инк. | Замещенные 2-арил-3-(гетероарил) имидазо [1,2-а] пиримидины, содержащие их фармацевтические композиции и связанные с ними способы |
| MXPA02004735A (es) | 1999-11-12 | 2003-01-28 | Orive Javier Uhthoff | Compuestos heteroaromaticos, biciclicos y triciclicos. |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| IL156567A0 (en) | 2001-03-09 | 2004-01-04 | Pfizer Prod Inc | Triazolopyridines as anti-inflammatory agents |
| GB0107751D0 (en) | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
| JPWO2002094809A1 (ja) | 2001-05-24 | 2004-09-09 | 山之内製薬株式会社 | ３−キノリン−２（１ｈ）−イリデンインドリン−２−オン誘導体 |
| EP1481977A4 (en) | 2002-03-01 | 2006-02-01 | Astellas Pharma Inc | NITROGENIC HETEROCYCLIC COMPOUND |
| WO2003080621A1 (en) | 2002-03-19 | 2003-10-02 | Merck & Co., Inc. | Process and intermediates to substituted imidazopyrimidines |
| US6790852B2 (en) | 2002-04-18 | 2004-09-14 | Hoffmann-La Roche Inc. | 2-(2,6-dichlorophenyl)-diarylimidazoles |
| GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0210127D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
| DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| PA8580301A1 (es) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| EP1537107A2 (en) | 2002-08-30 | 2005-06-08 | Pfizer Products Inc. | Novel processes and intermediates for preparing triazolo-pyridines |
| US6784297B2 (en) | 2002-09-04 | 2004-08-31 | Kopran Limited | Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate |
| ATE473980T1 (de) | 2002-12-18 | 2010-07-15 | Vertex Pharma | Triazolopyridazine als proteinkinase-inhibitoren |
| RS53118B (sr) | 2003-02-26 | 2014-06-30 | Sugen Inc. | Aminoheteroaril jedinjenja kao inhibitori protein kinaze |
| EP1640010A1 (en) | 2003-07-01 | 2006-03-29 | Astellas Pharma Inc. | Agent inducing increase in bone mass |
| JP2007516180A (ja) | 2003-07-02 | 2007-06-21 | スゲン，インコーポレイティド | ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類 |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| US7037909B2 (en) | 2003-07-02 | 2006-05-02 | Sugen, Inc. | Tetracyclic compounds as c-Met inhibitors |
| EP1644362A2 (en) | 2003-07-02 | 2006-04-12 | Sugen, Inc. | Indolinone hydrazides as c-met inhibitors |
| WO2005014598A1 (en) | 2003-07-30 | 2005-02-17 | Laboratorios S.A.L.V.A.T., S.A. | Substituted imidazopyrimidines for the prevention and treatment of cancer |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| EP1697352B1 (en) | 2003-09-24 | 2012-06-27 | Vertex Pharmceuticals Incorporated | 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| US7144889B2 (en) | 2003-10-16 | 2006-12-05 | Hoffman-La Roche Inc. | Triarylimidazoles |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| JP4932495B2 (ja) | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
| CA2553433A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer |
| WO2005077953A1 (ja) | 2004-02-18 | 2005-08-25 | Banyu Pharmaceutical Co., Ltd. | 含窒素縮合へテロ芳香環誘導体 |
| HRP20090495T1 (hr) | 2004-04-02 | 2009-10-31 | Osi Pharmaceuticals | Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom |
| US20050277650A1 (en) | 2004-04-20 | 2005-12-15 | Sundaram Venkataraman | Process for preparing aripirazole hydrate |
| AU2005245386B2 (en) | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| WO2005121125A1 (en) | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
| WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| AR053090A1 (es) * | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
| EP2264033A1 (en) | 2004-07-27 | 2010-12-22 | SGX Pharmaceuticals, Inc. | 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS |
| GEP20104906B (en) | 2004-08-26 | 2010-02-25 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| AU2005301568B2 (en) | 2004-11-08 | 2011-06-09 | Msd K.K. | Novel fused imidazole derivative |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| JP5236293B2 (ja) | 2005-01-13 | 2013-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｘｉａ因子阻害剤としての置換ビアリール化合物 |
| JP2008540535A (ja) | 2005-05-12 | 2008-11-20 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
| EP1904501A2 (en) | 2005-07-11 | 2008-04-02 | Smithkline Beecham Corporation | Chemical compounds |
| WO2007015866A2 (en) | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
| JP2009502734A (ja) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| CA2630884A1 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| HUE030390T2 (en) | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| DK1973545T3 (da) | 2005-12-23 | 2013-02-25 | Ariad Pharma Inc | Bicykliske heteroarylforbindelser |
| WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| JP2010500365A (ja) | 2006-08-07 | 2010-01-07 | インサイト・コーポレイション | キナーゼ阻害剤としてのトリアゾロトリアジン |
| WO2008036272A1 (en) * | 2006-09-18 | 2008-03-27 | Vertex Pharmaceuticals Incorporated | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF |
| KR101083177B1 (ko) * | 2006-10-23 | 2011-11-11 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 트리아졸로-피리다진 단백질 키나제 조정제 |
| MY146474A (en) | 2006-11-06 | 2012-08-15 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| ES2560435T3 (es) * | 2006-11-22 | 2016-02-19 | Incyte Holdings Corporation | Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa |
| KR101156845B1 (ko) | 2007-05-21 | 2012-06-18 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 헤테로시클릭 키나제 조절제 |
| MX393622B (es) * | 2008-05-21 | 2025-03-24 | Incyte Corp | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas. |
| JP5714030B2 (ja) | 2010-02-03 | 2015-05-07 | インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン |
-
2009
- 2009-05-20 MX MX2019011954A patent/MX393622B/es unknown
- 2009-05-20 KR KR1020107028754A patent/KR101706784B1/ko active Active
- 2009-05-20 EP EP17172014.7A patent/EP3287449A3/en not_active Withdrawn
- 2009-05-20 MY MYPI2014001739A patent/MY187131A/en unknown
- 2009-05-20 LT LTEP09751439.2T patent/LT2300455T/lt unknown
- 2009-05-20 CA CA2724742A patent/CA2724742C/en active Active
- 2009-05-20 JP JP2011510669A patent/JP6022158B2/ja active Active
- 2009-05-20 MY MYPI2010005346A patent/MY155565A/en unknown
- 2009-05-20 TW TW98116761A patent/TWI472529B/zh active
- 2009-05-20 NZ NZ589622A patent/NZ589622A/xx unknown
- 2009-05-20 BR BRPI0912882A patent/BRPI0912882A2/pt not_active Application Discontinuation
- 2009-05-20 CN CN201810253971.5A patent/CN108586463A/zh active Pending
- 2009-05-20 WO PCT/US2009/044622 patent/WO2009143211A2/en not_active Ceased
- 2009-05-20 HU HUE09751439A patent/HUE034716T2/hu unknown
- 2009-05-20 CN CN202110581794.5A patent/CN113248510B/zh active Active
- 2009-05-20 MY MYPI2018000893A patent/MY199552A/en unknown
- 2009-05-20 SI SI200931744T patent/SI2300455T1/sl unknown
- 2009-05-20 MX MX2010012718A patent/MX2010012718A/es active IP Right Grant
- 2009-05-20 CL CL2009001250A patent/CL2009001250A1/es unknown
- 2009-05-20 NZ NZ602791A patent/NZ602791A/en unknown
- 2009-05-20 HR HRP20171528TT patent/HRP20171528T1/hr unknown
- 2009-05-20 US US12/469,360 patent/US8420645B2/en active Active
- 2009-05-20 PL PL09751439T patent/PL2300455T3/pl unknown
- 2009-05-20 ES ES09751439.2T patent/ES2643363T3/es active Active
- 2009-05-20 DK DK09751439.2T patent/DK2300455T3/en active
- 2009-05-20 MX MX2013009914A patent/MX368802B/es unknown
- 2009-05-20 EA EA201071337A patent/EA021364B1/ru not_active IP Right Cessation
- 2009-05-20 CN CN200980123120.8A patent/CN102083814B/zh active Active
- 2009-05-20 CN CN201410110793.2A patent/CN103936743B/zh active Active
- 2009-05-20 EP EP09751439.2A patent/EP2300455B1/en active Active
- 2009-05-20 PT PT97514392T patent/PT2300455T/pt unknown
- 2009-05-21 AR ARP090101835A patent/AR071873A1/es not_active Application Discontinuation
-
2010
- 2010-11-10 IL IL209229A patent/IL209229A/en active IP Right Grant
- 2010-11-16 ZA ZA2010/08212A patent/ZA201008212B/en unknown
- 2010-11-26 CO CO10149434A patent/CO6300934A2/es active IP Right Grant
- 2010-12-16 EC EC2010010685A patent/ECSP10010685A/es unknown
- 2010-12-20 MA MA33445A patent/MA32405B1/fr unknown
-
2013
- 2013-03-11 US US13/793,864 patent/US8901123B2/en active Active
- 2013-11-04 IL IL229229A patent/IL229229A/en active IP Right Grant
-
2014
- 2014-10-28 US US14/525,381 patent/US20150148348A1/en not_active Abandoned
-
2015
- 2015-03-02 JP JP2015040617A patent/JP6105653B2/ja active Active
-
2016
- 2016-11-18 US US15/355,630 patent/US10245265B2/en active Active
- 2016-12-19 IL IL249651A patent/IL249651A/en active IP Right Grant
-
2017
- 2017-10-18 CY CY20171101085T patent/CY1119813T1/el unknown
-
2018
- 2018-04-26 AR ARP180101072A patent/AR111428A2/es active IP Right Grant
- 2018-08-28 HK HK18111067.5A patent/HK1251568A1/en unknown
-
2019
- 2019-02-07 US US16/269,871 patent/US10799509B2/en active Active
-
2020
- 2020-09-08 US US17/014,414 patent/US11452726B2/en active Active
-
2021
- 2021-08-12 AR ARP210102275A patent/AR123240A2/es unknown
-
2022
- 2022-08-18 US US17/820,779 patent/US12427154B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249651A0 (en) | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[b-2,1] 4,2,1]]triazin-2-yl]benzamide and processes related to their preparation | |
| ZA201304646B (en) | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
| AP2012006631A0 (en) | 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors | |
| AP3417A (en) | Pyrazolo [1,5-a] pyrimidines as antiviral agents | |
| IL219424A0 (en) | IMIDAZO [1,2-b] PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | |
| IL214436A0 (en) | 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators | |
| ZA201306719B (en) | 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
| IL227526A0 (en) | Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors | |
| ZA201302128B (en) | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
| ZA201107350B (en) | Imidazo [2 1 b] [1, 3, 4] thiadiazole derivatives | |
| ZA201403441B (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid | |
| IL229993A0 (en) | A process for the preparation of 8-Alkoxy[1,2,4]triazolo[5,1-c]pyrimidine-2 amines 5-converted | |
| PT2448940E (pt) | Derivados de 6,7,8,9-tetra-hidro-pirimido{1,2-α} pirimidin- 4-ona, sua preparação e sua utilização farmacêutica | |
| ZA201103787B (en) | Absorbent article with waist relief feature | |
| IL217294A0 (en) | Novel 2,3 - dihydro -1h -imidazo (1,2-a)pyrimidin -5-one derivatives, preparation thereof, and pharamceutical use thereof | |
| IL216794A0 (en) | 3-substituted-8-substituted-3h imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use | |
| IL219116A (en) | 5h– oxo- (Theo / oxa) Zulu [a – 2,3] ortho-compressed pyrimidine with other rings and their use for treating anemia and tissue damage caused by ischemic diseases | |
| IL220448A (en) | Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses | |
| ZA201008178B (en) | Imidazo [2,1-b]quinazolin-2-one derivatives and their use as platelet anti-aggregative agents | |
| IL215521A0 (en) | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | |
| GB0725077D0 (en) | Antifolate com[ounds for the treatment of melanoma |